Organization reports progress on multiple fronts in the PTSD arena, including policy, research, advancing therapeutics and personalized medicine
Cohen Veterans Bioscience (CVB), a translational research public charity organization dedicated to fast-tracking personalized diagnostics and therapeutics for brain health, today provides a progress update on critical post-traumatic stress disorder (PTSD) programs, and issues proceedings from the first State of the Science Summit focused on PTSD.
Since the launch in November 2015 of its Veterans-focused programming, CVB has set an aggressive roadmap to ensure precision diagnosis and targeted therapeutics are a focus of national efforts and milestone-driven research:
Beyond the Million Veterans Program: Barriers to Precision Medicine
Psychiatric Genomics Consortium PTSD Group (PGC-PTSD): Landmark Study
State of the Science Summit on Post-traumatic Stress Disorder: Proceedings
Award-Winning Solution for Insomnia: SleepWell
Progressing Therapeutics: Adaptive Platform Trial
Advancing A Personalized Medicine Approach: Brain Imaging Biomarker Study
In our first three years, our Veteran-focused goal was to build a fundamental infrastructure which enables us to find a PTSD diagnostic and pave the way for therapeutic studies. We are delivering upon the approach and leveraging enabling platforms to deliver these results across many fronts,” said Magali Haas, President and CEO, Cohen Veterans Bioscience. We are pleased with the progress of our alliance network, and with the continued collaborative efforts of our colleagues across the field we can advance PTSD solutions that much sooner. Our Veterans, and others who suffer from the devastating effects of PTSD, deserve it.”
Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.
Please feel free to email us at email@example.com